Literature DB >> 2034693

Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments.

A H Kaplan1, R Swanstrom.   

Abstract

The structural proteins of the retroviral capsid are translated as a polyprotein (the Gag precursor) that is cleaved by a virally encoded protease. Processing of the human immunodeficiency virus type 1 Gag precursor Pr55 was analyzed through a combination of pulse-chase labeling, cell fractionation, and immunoprecipitation. We observed a membrane-associated processing pathway for the Gag precursor that gives rise to virions. In addition, we found that a significant amount of processing occurs in the cytoplasm of infected cells resulting in the intracellular accumulation of appropriately processed viral proteins. This observation suggests the viral protease is active in the cytoplasmic compartment of the cell. Processing of the Gag protein was blocked in both compartments by the addition of a viral protease inhibitor. A comparison of the amount of cytoplasmic processing seen in lytically infected cells with that seen in chronically infected cells showed that cytoplasmic processing was associated with the lytic infection. These observations raise the possibility that activation of the human immunodeficiency virus type 1 protease in the cytoplasm of lytically infected cells might result in the cleavage of cellular proteins and thus contribute to cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2034693      PMCID: PMC51694          DOI: 10.1073/pnas.88.10.4528

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  Retroviral proteinases.

Authors:  S Oroszlan; R B Luftig
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Inhibition of translation by poliovirus: inactivation of a specific initiation factor.

Authors:  J K Rose; H Trachsel; K Leong; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

3.  Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.

Authors:  J Sodroski; W C Goh; C Rosen; K Campbell; W A Haseltine
Journal:  Nature       Date:  1986 Jul 31-Aug 6       Impact factor: 49.962

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins.

Authors:  S Crawford; S P Goff
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

6.  Determinants for receptor interaction and cell killing on the avian retrovirus glycoprotein gp85.

Authors:  A J Dorner; J M Coffin
Journal:  Cell       Date:  1986-05-09       Impact factor: 41.582

7.  Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity.

Authors:  I Katoh; Y Yoshinaka; A Rein; M Shibuya; T Odaka; S Oroszlan
Journal:  Virology       Date:  1985-09       Impact factor: 3.616

8.  Mutations in the gag gene of Moloney murine leukemia virus: effects on production of virions and reverse transcriptase.

Authors:  P Schwartzberg; J Colicelli; M L Gordon; S P Goff
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

9.  Correlation between cell killing and massive second-round superinfection by members of some subgroups of avian leukosis virus.

Authors:  S K Weller; A E Joy; H M Temin
Journal:  J Virol       Date:  1980-01       Impact factor: 5.103

10.  Relationship of retrovirus polyprotein cleavages to virion maturation studied with temperature-sensitive murine leukemia virus mutants.

Authors:  O N Witte; D Baltimore
Journal:  J Virol       Date:  1978-06       Impact factor: 5.103

View more
  77 in total

1.  Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.

Authors:  P O Falnes; R Welker; H G Kräusslich; S Olsnes
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH.

Authors:  D Xie; S Gulnik; E Gustchina; B Yu; W Shao; W Qoronfleh; A Nathan; J W Erickson
Journal:  Protein Sci       Date:  1999-08       Impact factor: 6.725

3.  Activation of the Mason-Pfizer monkey virus protease within immature capsids in vitro.

Authors:  S D Parker; E Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

4.  HIV-1 protease cleaves eukaryotic initiation factor 4G and inhibits cap-dependent translation.

Authors:  I Ventoso; R Blanco; C Perales; L Carrasco
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

5.  Structural consequences of cyclophilin A binding on maturational refolding in human immunodeficiency virus type 1 capsid protein.

Authors:  L Dietrich; L S Ehrlich; T J LaGrassa; D Ebbets-Reed; C Carter
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

7.  The late stage of human immunodeficiency virus type 1 assembly is an energy-dependent process.

Authors:  M Tritel; M D Resh
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

8.  Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Authors:  N L Davis; I J Caley; K W Brown; M R Betts; D M Irlbeck; K M McGrath; M J Connell; D C Montefiori; J A Frelinger; R Swanstrom; P R Johnson; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

9.  Phosphorylation and proteolytic cleavage of gag proteins in budded simian immunodeficiency virus.

Authors:  Sarah M Rue; Jason W Roos; Patrick M Tarwater; Janice E Clements; Sheila A Barber
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

10.  An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

Authors:  J Konvalinka; M A Litterst; R Welker; H Kottler; F Rippmann; A M Heuser; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.